UPDATE 1-GSK sues Pfizer in US for patent infringement over RSV vaccine

[admin]

British biopharmaceutical giant GSK sued Pfizer in federal court in Delaware on Wednesday, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's patent rights in its rival RSV shot Arexvy. GSK said Pfizer's vaccine infringes four of its patents related to the antigen its shots use to fight the respiratory disease. Pfizer and GSK are running a tight race to tap into the RSV vaccine market, which could exceed $10 billion by 2030, according to analysts.